Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Evans, Jennifer R; Lawrenson, John G

doi:10.1002/14651858.cd000254.pub5

Cited by 5 publications

(7 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antioxidants such as lutein, zeaxanthin [37], and vitamin C [38] have been shown to confer significant benefits to ocular health, contributing to maintaining healthy eyes. These antioxidants play crucial roles in preventing oxidative stress within ocular tissues, thereby helping to preserve visual function and protect against age-related degenerative changes and cataracts [39].…”

Section: Antioxidants and Eye Healthmentioning

confidence: 99%

Cellular ROS and Antioxidants: Physiological and Pathological Role

Kozlov,

Javadov,

Sommer

2024

Antioxidants

View full text Add to dashboard Cite

show abstract

Section: Antioxidants and Eye Healthmentioning

confidence: 99%

Cellular ROS and Antioxidants: Physiological and Pathological Role

Kozlov,

Javadov,

Sommer

2024

Antioxidants

View full text Add to dashboard Cite

show abstract

“…These drusen cause gradual damage to the light-sensitive cells, leading to progressive vision loss. Conversely, wet-form AMD involves the growth of abnormal blood vessels beneath the macula, which leads to the leakage of blood and fluid into the retina [226]. The disruption in the balance between the creation of damaged cellular components and their degradation results in the accumulation of harmful products, such as intracellular lipofuscin and extracellular drusen.…”

Section: Age-related Macular Degenerationmentioning

confidence: 99%

Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery

Rojekar,

Parit,

Gholap

et al. 2024

Preprint

View full text Add to dashboard Cite

Microneedle technology is a novel platform technology that revolutionizes ocular drug delivery and addresses critical challenges in the treatment of ocular diseases. Routine treatment methods, such as eye drops and intravitreal injections, suffer from low bioavailability and poor patient compliance. So, novel advanced platform technologies are required to overcome these challenges. Microneedle is a minimally invasive and promising alternative technique that helps precisely control drug delivery to targeted tissues and organs. This review investigates the potential impact of microneedle technology for eye care, underscoring recent advancements, underlying mechanisms, and emerging preclinical and clinical uses. Different types of microneedles, including solid, coated, dissolvable, and hollow, have demonstrated their potential and capability to bypass several barriers in the cornea and sclera. This ensures effective drug penetration and delivery. The current innovations in material science and fabrication methods have enhanced the safety and efficacy of microneedles, reducing discomfort and the chances of infections. These microneedle technologies offer sustained and controlled drug delivery, which could improve therapeutic outcomes for various disease conditions like age-related macular degeneration, glaucoma, diabetic neuropathy, etc. In the current review, recent preclinical and clinical studies emphasize microneedle-based ocular drug delivery's feasibility and potential benefits. These include improved pharmacokinetics, reduced dosing frequency, enhanced patient adherence, and, most importantly, microneedles offer versatile platforms for delivering a wide range of small and large molecules and gene therapies. Despite the exciting progress, obstacles such as regulatory barriers, scalability, and long-term biocompatibility persist. It will be essential to tackle these challenges through interdisciplinary research and partnerships to integrate microneedle technology into standard clinical use effectively. Ultimately, microneedle drug delivery offers a revolutionary method that has the potential to significantly enhance the treatment and results of ocular diseases, marking the dawn of a new era in eye care.

show abstract

“…While clinical findings in AMD pointed to inflammation as the central driver of AMD progression, initial therapeutics for AMD were focused on anti-oxidation. To this day, the only consensus treatment for early/intermediate-stage AMD is the use of antioxidant therapies studied in a large National Eye Institute study called the Age-Related Eye Disease Study 1 and 2 (AREDS 1 and 2) [43]. This study has produced over 28 reports and countless publications on the benefit of anti-oxidant therapy for the prevention of late AMD progression [44].…”

Section: Anti-oxidant Therapy For Early-stage Amdmentioning

confidence: 99%

Sialic Acid Mimetic Microglial Sialic Acid-Binding Immunoglobulin-like Lectin Agonism: Potential to Restore Retinal Homeostasis and Regain Visual Function in Age-Related Macular Degeneration

Tolentino,

Tolentino

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Age-related macular degeneration (AMD), a leading cause of visual loss and dysfunction worldwide, is a disease initiated by genetic polymorphisms that impair the negative regulation of complement. Proteomic investigation points to altered glycosylation and loss of Siglec-mediated glyco-immune checkpoint parainflammatory and inflammatory homeostasis as the main determinant for the vision impairing complications of macular degeneration. The effect of altered glycosylation on microglial maintained retinal para-inflammatory homeostasis and eventual recruitment and polarization of peripheral blood monocyte-derived macrophages (PBMDMs) into the retina can explain the phenotypic variability seen in this clinically heterogenous disease. Restoring glyco-immune checkpoint control with a sialic acid mimetic agonist targeting microglial/macrophage Siglecs to regain retinal para-inflammatory and inflammatory homeostasis is a promising therapeutic that could halt the progression of and improve visual function in all stages of macular degeneration.

show abstract

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Abstract: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.

Cited by 5 publications

References 144 publications

Cellular ROS and Antioxidants: Physiological and Pathological Role

Cellular ROS and Antioxidants: Physiological and Pathological Role

Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery

Sialic Acid Mimetic Microglial Sialic Acid-Binding Immunoglobulin-like Lectin Agonism: Potential to Restore Retinal Homeostasis and Regain Visual Function in Age-Related Macular Degeneration

Contact Info

Product

Resources

About